SH
Sandra Herrmann
Mayo Clinic Minnesota
Research areas: Medicine · Nephrology · Acute Kidney Injury Research · Cancer Immunotherapy and Biomarkers · Renal and Vascular Pathologies
0000-0002-3700-4537
Employment
-
Mayo Clinic Minnesota Associate Professor of Medicine2013 - Present
Education
Education history is unavailable.
Projects & Funding
-
Hypoxic preconditioning for the improvement of the regenerative capacity of adipose-derived mesenchymal stem cells and its application in chronic kidney disease due to hypertensive nephropathy National Institute of Diabetes and Digestive and Kidney Diseases2018 - 2023
Publications (83)
- C5 Inhibition for Anti-Cancer Therapy-Induced Renal Thrombotic Microangiopathy Save
- Immune Checkpoint Inhibitor–Associated Acute Kidney Injury Save
- Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis Save
- Drug-Induced Thrombotic Microangiopathy in Cancer Save
- Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines Save
- The Diagnosis of Acute Interstitial Nephritis: From Classic Drug Toxicity to Immune Checkpoint Inhibitor–Related Disease Save
- Kidney toxicities of modern cancer immunotherapies: Mechanisms, diagnosis, and management Save
- F18-FDG PET–CT in immune checkpoint inhibitor-associated acute interstitial nephritis: what is the diagnostic value? Save
- Up to Date on Onconephrology: Navigating Kidney Challenges in Patients with Cancer Save
- Glomerular pathology of vascular endothelial growth factor inhibition—A 12-year review at the Mayo Clinic Save
- Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells Save
- Reinforcing the role of magnesium in preventing cisplatin-induced nephrotoxicity: real-world evidence and clinical implications Save
- Ten tips for an onco-nephrology clinic Save
- Update on the Assessment of GFR in Patients with Cancer Save
- Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis Save
- Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy Save
- Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology Save
- Onconephrology Save
- Immune checkpoint inhibitor–associated nephritis—treatment standard Save
- Paraprotein-Mediated Glomerular Diseases Save